Chemoinformaics analysis of 11,13-Dehydrolanuginolide
| Molecular Weight | 306.358 | nRot | 1 |
| Heavy Atom Molecular Weight | 284.182 | nRig | 19 |
| Exact Molecular Weight | 306.147 | nRing | 3 |
| Solubility: LogS | -3.452 | nHRing | 2 |
| Solubility: LogP | 1.721 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 44 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 0 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 17 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 0 |
| nHA | 5 | APOL | 47.0694 |
| nHD | 0 | BPOL | 29.0146 |
| QED | 0.322 |
| Synth | 4.853 |
| Natural Product Likeliness | 3.764 |
| NR-PPAR-gamma | 0.868 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.031 |
| Pgp-sub | 0 |
| HIA | 0.551 |
| CACO-2 | -4.778 |
| MDCK | 0.000038 |
| BBB | 0.847 |
| PPB | 0.666491 |
| VDSS | 1.344 |
| FU | 0.386912 |
| CYP1A2-inh | 0.071 |
| CYP1A2-sub | 0.082 |
| CYP2c19-inh | 0.038 |
| CYP2c19-sub | 0.388 |
| CYP2c9-inh | 0.053 |
| CYP2c9-sub | 0.036 |
| CYP2d6-inh | 0.231 |
| CYP2d6-sub | 0.165 |
| CYP3a4-inh | 0.29 |
| CYP3a4-sub | 0.265 |
| CL | 5.584 |
| T12 | 0.771 |
| hERG | 0.034 |
| Ames | 0.133 |
| ROA | 0.745 |
| SkinSen | 0.746 |
| Carcinogencity | 0.175 |
| EI | 0.531 |
| Respiratory | 0.975 |
| NR-Aromatase | 0.76 |
| Antiviral | Yes |
| Prediction | 0.881179 |